• In the first quarter of 2026, Colgate-Palmolive reported sales of US$5,324 million, up from US$4,911 million a year earlier, while net income eased to US$646 million from US$690 million and diluted EPS slipped to US$0.80 from US$0.85.
• Despite pressure on margins from higher input costs, management kept its full-year 2026 net sales growth outlook of 2% to 6%, signaling confidence in its pricing and volume strategy across key markets.
• We’ll now examine how this combination of stronger sales, softer margins, and reaffirmed guidance affects Colgate-Palmolive’s investment narrative and outlook.

Invest in the nuclear renaissance through our list of 91 elite nuclear energy infrastructure plays powering the global AI revolution.

Colgate-Palmolive Investment Narrative Recap

To stay invested in Colgate-Palmolive, you need to believe its global brands and everyday categories can convert steady sales into dependable earnings, even when costs and consumer demand are uneven. The latest quarter’s stronger sales but weaker earnings suggest that, in the short term, the key catalyst is management’s ability to defend margins against higher input costs, while the biggest risk remains sustained pressure on profitability. Q1 results do not materially change that risk balance.

The most relevant recent announcement here is Colgate’s decision to maintain its full year 2026 net sales growth outlook of 2% to 6%, including a low single digit foreign exchange benefit. Holding that guidance after a quarter of higher sales but softer margins keeps attention squarely on whether pricing, productivity and mix can offset raw material and packaging cost inflation, which is central to the current catalyst around margin resilience.

Yet even with sales holding up, investors should be aware that persistent input cost inflation could...

Colgate-Palmolive's narrative projects $22.8 billion revenue and $3.5 billion earnings by 2029. This requires 3.8% yearly revenue growth and about a $1.4 billion earnings increase from $2.1 billion.

Uncover how Colgate-Palmolive's forecasts yield a $96.68 fair value, a 10% upside to its current price.

Exploring Other Perspectives

Five members of the Simply Wall St Community see Colgate-Palmolive’s fair value between US$78.22 and US$120.03, highlighting quite different views on upside. Set that against the current risk of ongoing raw material and packaging cost pressure, and it becomes even more important to compare several viewpoints on how resilient Colgate-Palmolive’s margins can be over time.

Explore 5 other fair value estimates on Colgate-Palmolive - why the stock might be worth as much as 37% more than the current price!

Reach Your Own Conclusion

Don't just follow the ticker - dig into the data and build a conviction that's truly your own.

• A great starting point for your Colgate-Palmolive research is our analysis highlighting 3 key rewards and 3 important warning signs that could impact your investment decision.
• Our free Colgate-Palmolive research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Colgate-Palmolive's overall financial health at a glance.

Interested In Other Possibilities?

The market won't wait. These fast-moving stocks are hot now. Grab the list before they run:

• The future of work is here. Discover the 33 top robotics and automation stocks leading the charge in AI-driven automation and industrial transformation.
• We've uncovered the 12 dividend fortresses yielding 5%+ that don't just survive market storms, but thrive in them.
• Rare earth metals are an input to most high-tech devices, military and defence systems and electric vehicles. The global race is on to secure supply of these critical minerals. Beat the pack to uncover the 33 best rare earth metal stocks of the very few that mine this essential strategic resource.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.